Skip to main content
ROQUEFORT THERAPEUTICS PLC logo

ROQUEFORT THERAPEUTICS PLC - Investor Relations & Filings

Listed IPO Mar 2021
Ticker · ROQ ISIN · GB00BMDQ2T15 LEI · 254900P4SISIWOR9RH34 IL Professional, scientific and technical activities
Open in API
Filings indexed 192 across all filing types
Latest filing 2026-05-06 Annual Report
Country GB United Kingdom
Listing IL ROQ · 3 venues

Key figures FY2025

Period ended 2025-12-31 · GBP
Headline annual figures for ROQUEFORT THERAPEUTICS PLC, fiscal year 2025, reported in GBP, with the source filing for each figure.
Total Revenues GBP 0 per the Annual Report filed 2026-05-06
Net Income GBP -3.36M per the Annual Report filed 2026-05-06
Total Equity GBP 2.42M per the Annual Report filed 2026-05-06
Cash from Ops GBP -645.62k per the Annual Report filed 2026-05-06

As reported by the issuer in the filings linked above. Figures are normalized for comparability; consult the source filing for the authoritative statement.

About ROQUEFORT THERAPEUTICS PLC

https://www.roquefortplc.com/

Roquefort Therapeutics PLC is a biotechnology company focused on developing next-generation, first-in-class medicines for hard-to-treat cancers. The company operates within the high-growth immuno-oncology market. Its portfolio consists of five novel, patent-protected, pre-clinical anti-cancer programs. These programs are designed to target cancers that have become resistant to existing therapies. Roquefort Therapeutics utilizes a distributed R&D model, combining its in-house expertise and laboratory facilities with a network of partnerships with leading academic cancer research centers to advance its development strategy.

Recent filings

Filing Released Lang Actions
Annual Report & Financial Statements
Annual Report Classification · 95% confidence The document is titled 'Annual Report & Financial Statements' and covers the audited results for the year ended 31 December 2025, which is a full fiscal year. It includes detailed information about strategic changes, financial transactions, board changes, clinical program updates, and future outlook. The text contains comprehensive financial and operational data typical of an annual report. It is not a brief announcement or a certification letter, nor is it a transcript, presentation, or interim report. The document length is substantial (15,000 characters), indicating it is the full report rather than a publication announcement. Therefore, the document fits the definition of an Annual Report (10-K). FY 2025
2026-05-06 English
Clinical Trial Update
Regulatory Filings Classification · 80% confidence The document is an RNS (Regulatory News Service) announcement providing a clinical trial update and strategic transition details for Coiled Therapeutics plc. It is not a full financial report, earnings release, or other specialized filing. As a business update issued via the London Stock Exchange’s RNS, it falls into the general regulatory filings category.
2026-04-08 English
Total Voting Rights
Declaration of Voting Results & Voting Rights Announcements Classification · 92% confidence The document is an RNS announcement under the FCA’s Disclosure and Transparency Rules, providing the total number of issued ordinary shares and voting rights (commonly referred to as a “Total Voting Rights” announcement). This falls under the category of Declaration of Voting Results & Voting Rights Announcements (Code: DVA).
2026-04-01 English
Admission to Trading and First Day of Dealings
Share Issue/Capital Change Classification · 85% confidence The document is an RNS announcement from the London Stock Exchange regarding the Admission to Trading of Coiled Therapeutics plc ordinary shares on AIM, following a successful £8.5 million fundraise via the issue of 85 million New Ordinary Shares at 10p each. It is not a full financial report but a regulatory announcement detailing a new share issuance and change in capital structure. This fits “Share Issue/Capital Change” (SHA).
2026-03-27 English
Investor Presentation
Investor Presentation Classification · 92% confidence The document is a London Stock Exchange RNS notice titled “Investor Presentation” announcing a live interactive presentation for investors to be hosted by the company’s leadership team on a specified date. It does not contain actual presentation slides or detailed financials but invites investors to register for the event. This matches the definition of an Investor Presentation (IP).
2026-03-26 English
Result of General Meeting
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is an RNS release announcing the results of a General Meeting, detailing votes for and against each resolution and withheld votes, along with changes in share listings and director participation. This matches the definition of Declaration of Voting Results & Voting Rights Announcements (DVA).
2026-03-26 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.